Filing Summary
Business Context and Reporting Period
Cullinan Oncology, Inc. filed a Form 8-K reporting results of its Annual Meeting of Stockholders held on June 22, 2022. The filing was signed June 24, 2022. The company is incorporated in Delaware, trades under the symbol CGEM on Nasdaq, and identified itself as an emerging growth company.
Financial Metrics and Capital Structure
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics. It also does not disclose financial guidance or a revised outlook.
Material Changes Versus the Prior Comparable Period
No operating or financial-period comparison is provided. The filing reports corporate governance matters only.
Meeting Results, Outlook, and Risks
- Stockholders elected Class II directors Ansbert Gadicke, M.D., and Anthony Rosenberg to three-year terms.
- Ansbert Gadicke, M.D.: 27,033,605 votes for, 10,667,725 votes withheld, and 4,141,978 broker non-votes.
- Anthony Rosenberg: 27,229,454 votes for, 10,471,876 votes withheld, and 4,141,978 broker non-votes.
- Stockholders ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Accounting-firm ratification results were 41,825,399 votes for, 12,030 against, 5,879 abstentions, and no broker non-votes.
- The filing text does not provide management commentary, business guidance, contingencies, unusual items, or specific risk updates.
Investor Verification Checklist
- Verify the elected directors’ continuing terms and board committee assignments in subsequent filings.
- Confirm KPMG LLP’s appointment and review subsequent filings for any change in auditor or reported accounting matters.
- Use the company’s periodic reports to assess operating results, cash runway, financing needs, debt, and clinical-development risks, none of which are addressed in this 8-K.
- Note that the filing names the registrant as Cullinan Oncology, Inc.; the provided metadata refers to Cullinan Therapeutics, Inc.